SEC Form 3 · accession 0001209191-18-052308
Urovant Sciences Ltd. · UROV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christine Ocampo
Officer — PFAO;CAO/Urovant Sciences,Inc.
Period of report
Sep 26, 2018
Accepted (ET)
Sep 26, 2018 · 4:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001740547
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | holding | — | — | — | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.64 | holding | — | — | — | — | Nov 19, 2027 | Common Shares | 133,500 | — | D |
Explanation of responses
- F125% of the total shares underlying the option shall vest and become exercisable on October 5, 2018; the remaining shares vest in 36 equal monthly installments over the following three years, providing continuous service to the Issuer through each such vesting date.
Remarks
Exhibit List - Exhibit 24.1 - Power of Attorney